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SUMMARY 
EML4-ALK is an oncogenic fusion present in ~5% non-small cell lung cancers. However, 
alternative breakpoints in the EML4 gene lead to distinct variants with different patient 
outcomes. Here, we show in cell models that EML4-ALK variant 3 (V3), which is linked to 
accelerated metastatic spread, causes microtubule stabilization, formation of extended 
cytoplasmic protrusions and increased cell migration. It also recruits the NEK9 and NEK7 
kinase to microtubules via the N-terminal EML4 microtubule-binding region. Overexpression 
of wild-type EML4 as well as constitutive activation of NEK9 also perturb cell morphology and 
accelerate migration in a microtubule-dependent manner that requires the downstream kinase 
NEK7 but not ALK activity. Strikingly, elevated NEK9 expression is associated with reduced 
progression-free survival in EML4-ALK patients. Hence, we propose that EML4-ALK V3 
promotes microtubule stabilization through NEK9 and NEK7 leading to increased cell 
migration. This represents a novel actionable pathway that could drive metastatic disease 








































The EML4-ALK translocation is an oncogenic driver in a subset of lung cancers resulting from 
an inversion on the short arm of chromosome 2. This creates an in-frame fusion of an N-
terminal fragment of the echinoderm microtubule-associated protein-like 4, EML4 (Li and 
Suprenant, 1994; Suprenant et al., 1993), to the C-terminal tyrosine kinase domain of the 
anaplastic lymphoma kinase, ALK. The fusion was first identified in non-small-cell lung cancer 
(NSCLC), where it is present in ~5% of cases, but has since been identified in other tumour 
types, including breast and colorectal cancers (Lin et al., 2009; Rikova et al., 2007; Soda et 
al., 2007). The majority of EML4-ALK lung cancers, respond remarkably well to catalytic 
inhibitors of the ALK tyrosine kinase, such as crizotinib. However, this approach is not 
curative as acquired resistance to ALK inhibitors is inevitable due to either secondary 
mutations in the ALK tyrosine kinase domain or off-target alterations that switch dependence 
to other signalling pathways (Choi et al., 2010; Crystal et al., 2014; Hrustanovic et al., 2015; 
Kwak et al., 2010; McCoach et al., 2018; Shaw et al., 2013). Consequently, alternative 
therapies capable of selectively targeting ALK inhibitor resistant lung cancers are warranted. 
 
It is clear that not all EML4-ALK patients respond well to ALK inhibitors in the first place (Woo 
et al., 2017). One potential explanation is the presence of alternative EML4-ALK variants that 
arise from distinct breakpoints (Bayliss et al., 2016; Choi et al., 2008). All fusions encode the 
C-terminal catalytic domain of the ALK kinase and an N-terminal coiled-coil from EML4 that 
promotes oligomerization and autophosphorylation. However, alternative breakpoints in the 
EML4 gene lead to variable amounts of EML4 being present in the fusions. The N-terminal 
coiled-coil of EML4 (residues 14-63) has been shown by X-ray crystallography to form trimers 
(Richards et al., 2015). This sequence is followed by an unstructured region of approximately 
150 residues rich in serine, threonine and basic residues. Based on crystallographic analysis 
of the related EML1 protein, the ~600 residue C-terminal region of EML4 (residues 216-865) 
is predicted to fold into a tandem pair of atypical -propellers termed the TAPE domain 
(Richards et al., 2014). Structure-function studies have shown that while the C-terminal TAPE 
domain binds to -tubulin heterodimers, it is the N-terminal domain (NTD) encompassing 
the coiled-coil and unstructured region that promotes binding to polymerized microtubules 
(Richards et al., 2014; Richards et al., 2015). 
 
While all EML4-ALK fusion proteins have the trimerization motif, the distinct breakpoints 
mean that the different variants encode more or less of the unstructured and TAPE domains. 
Thus, the longer variants, V1 and V2, encode the unstructured domain and a partial fragment 
of the TAPE domain, while the shorter variants, V3 and V5, have none of the TAPE domain. 
Interestingly, the presence of a TAPE domain fragment renders the V1 and V2 fusion proteins 

































Richards et al., 2014). Indeed, binding to HSP90 may interfere with microtubule association 
as these longer variants localise poorly to the microtubule network despite containing the 
microtubule-binding region (Richards et al., 2015). In theory, this identifies an alternative 
therapeutic approach for patients with the longer variants through use of HSP90 inhibitors, 
although to date clinical trials of HSP90 inhibitors have not shown efficacy in ALK-positive 
patients (Chatterjee et al., 2016; Chen et al., 2010; Workman and van Montfort, 2014). 
Moreover, HSP90 inhibitors would not be useful in patients with EML4-ALK V3 or V5 as these 
fusion proteins are not dependent upon HSP90 for their expression. Furthermore, patients 
with V3 respond less well to ALK inhibitors suggesting additional tumorigenic mechanisms 
that may be independent of ALK activity (Woo et al., 2017). This is important as V3 
represents up to 50% of EML4-ALK fusions in NSCLC (Choi et al., 2010; Choi et al., 2008; 
Christopoulos et al., 2018; Sasaki et al., 2010; Woo et al., 2017). 
 
Wild-type EML proteins have been found to interact with members of the human NEK kinase 
family (Ewing et al., 2007). The human genome encodes eleven NEKs, named NEK1 to 
NEK11, many of which exhibit cell cycle-dependent activity and have functions in microtubule 
organization (Fry et al., 2017; Fry et al., 2012; Moniz et al., 2011). NEK9, NEK6 and NEK7 
are activated in mitosis and act together to regulate mitotic spindle assembly with NEK9 
upstream of NEK6 and NEK7 (Sdelci et al., 2011). NEK6 and NEK7 are the shortest of the 
NEKs consisting solely of a kinase domain with a short N-terminal extension that determines 
their substrate specificity (de Souza et al., 2014; Vaz Meirelles et al., 2010). Moreover, they 
are ~85% identical within their catalytic domains. NEK9 is one of the longest NEKs, consisting 
of an N-terminal catalytic domain (residues 52-308) followed by a C-terminal regulatory region 
(residues 309-979). Within this C-terminal region is an RCC1 (regulator of chromatin 
condensation 1)-like domain (residues 347-726) that is predicted to fold into a seven-bladed 
-propeller. Biochemical studies indicate that deletion of the RCC1-like domain causes 
constitutive activation of NEK9, indicating that it acts as an auto-inhibitory domain (Roig et al., 
2002). This domain is followed by a C-terminal tail that contains a coiled-coil motif (residues 
891-939) that promotes NEK9 dimerization (Roig et al., 2002). NEK9 directly interacts with 
NEK7, and presumably NEK6, through a short sequence (residues 810-828) that lies 
between the RCC1-like domain and coiled-coil (Haq et al., 2015). NEK9 stimulates NEK6 and 
NEK7 kinase activity by multiple mechanisms, including activation loop phosphorylation, 
dimerization-induced autophosphorylation, and allosteric binding-induced reorganization of 
catalytic site residues (Belham et al., 2003; Haq et al., 2015; Richards et al., 2009). 
 
Here, we demonstrate that expression of not only activated NEK9 and NEK7 kinases but also 
full-length EML4 and the short EML4-ALK variants that bind microtubules (V3 and V5) alter 
cell morphology and promote cell migration. These changes are not seen in cells expressing 

































interaction between the EML4 NTD and NEK9, and suggest a model in which the EML4-ALK 
V3 and V5 proteins stabilise microtubules and perturb cell behaviour through recruitment of 
NEK9 and NEK7 to microtubules. Finally, we show that EML4-ALK lung cancer patients 
exhibit a significant correlation between expression of V3/V5 and high levels of NEK9 protein, 
and that elevated NEK9 expression is associated with worse progression-free survival raising 
the prospect of novel therapeutic approaches for these patients. 
 
RESULTS 
Constitutively-active NEK9 alters interphase cell morphology and stabilises 
microtubules 
We initially set out to explore the function of NEK9 by analysing the consequences of its 
untimely activation in interphase cells. For this, an inducible system was established in which 
expression of myc-tagged wild-type NEK9, a full-length kinase-inactive mutant (K81M), and a 
constitutively-activated mutant lacking the RCC1-like domain (RCC1) was placed under the 
control of a tetracycline-inducible promoter in U2OS osteosarcoma cells (Fig. 1A). Western 
blots indicated time-dependent induction of expression of all three recombinant proteins upon 
addition of doxycycline, while subcellular localization confirmed the previously described 
cytoplasmic localization of the full-length and activated (RCC1) proteins, and nuclear 
localization of the catalytically-inactive mutant (Roig et al., 2002) (Fig. 1B; and Supp. Fig. 
S1A). Flow cytometry indicated no significant change in cell cycle distribution upon induction 
of these NEK9 proteins (Supp. Fig. S1B). Unexpectedly, brightfield and immunofluorescence 
microscopy revealed that induction of activated NEK9 led to a change in interphase cell 
morphology with formation of long cytoplasmic protrusions that were not seen upon induction 
of either wild-type or catalytically-inactive NEK9 (Fig. 1C-E and Supp. Fig. S1C). Time-lapse 
imaging indicated that these protrusions were comparatively stable structures that did not 
undergo retraction except during cell division (Fig 1F). Depolymerisation of the microtubule 
network with nocodazole or vinorelbine caused loss of these protrusions indicating that they 
are microtubule-dependent (Fig. 1G), while super-resolution microscopy revealed that 
protrusions contained not only microtubules and the activated NEK9 protein, but also actin 
and acetylated tubulin (Fig. 1H, I). Western blotting confirmed that induction of activated 
NEK9 was associated with an increased overall expression of acetylated tubulin, a marker of 
stabilised microtubules (Fig. 1J). Consistent with this, time-lapse imaging of live cells 
incubated with the fluorescent SiR-tubulin probe (Lukinavicius et al., 2014) demonstrated that 
microtubules were more resistant to nocodazole-induced depolymerization following induction 
of the activated NEK9 kinase (Fig. 1K; and Supp. Fig. S1D). Hence, activation of NEK9 leads 
to a microtubule-dependent change in interphase cell morphology characterised by formation 


































Activated NEK9 stimulates cell migration 
Time-lapse imaging of cells expressing the activated NEK9 construct suggested that these 
cells not only underwent a change in morphology but also exhibited increased migration. To 
test whether activated NEK9 alters parameters of cell migration, the rate of closure of a 
scratch wound on 2D cell culture plates was measured. This revealed that cells induced to 
express the activated NEK9 closed the wound more quickly than cells containing an empty 
vector or cells containing the activated NEK9 construct but without induction (Fig. 2A, B). This 
did not appear to result from increased persistence in directional migration into the wound as 
these cells migrated with reduced straightness compared to control cells (Fig. 2C). Individual 
cell tracking experiments in sparsely plated cells confirmed a significant increase in the 
velocity of migration as well the distance travelled in isolated cells induced to express 
activated NEK9 (Fig. 2D-F). Furthermore, in the absence of a chemoattractant, there was a 
decrease in the straightness of migration in isolated cells in the presence of activated NEK9 
consistent with more frequent changes in direction of migration (Fig. 2G). Finally, continuous 
monitoring of cell migration using a real-time transwell migration assay provided further 
evidence that induction of activated NEK9 led to an increased rate of migration; this was 
evident at 10 hours after induction and is therefore is not a result of increased proliferation 
(Fig. 2H, I). This assay measures 2D migration in response to serum suggesting that 
accelerated migration can occur in a directional manner in the presence of a chemoattractant 
as might be expected if growth factor receptors are expressed on the cytoplasmic protrusions. 
Taken together, these data demonstrate that activated NEK9 not only leads to a change in 
interphase cell morphology but also enhances cell migration. 
 
NEK9-induced changes in cell morphology and migration are dependent on NEK7 
A major function of NEK9 activity in mitosis is to activate NEK6 and NEK7 (Fry et al., 2017). 
This is thought to occur via both phosphorylation of activation loop residues and allosteric 
binding (Belham et al., 2003; Richards et al., 2009). Indeed, biochemical and structural 
studies have revealed direct interaction between residues 810-828 of NEK9 and a groove on 
the C-terminal lobe of the NEK7 catalytic domain (Haq et al., 2015). To determine whether 
the change in interphase cell morphology and migration induced by activated NEK9 is 
dependent on NEK6 or NEK7, cells expressing activated NEK9 were depleted of NEK6 or 
NEK7 (Supp. Fig. S2A). Quantitative imaging revealed that, in contrast to mock- or NEK6-
depleted cells that still exhibited extended cytoplasmic protrusions upon induction of activated 
NEK9, depletion of NEK7 prevented formation of these protrusions (Fig. 3A and Supp. Fig. 
S2B). This suggested that this phenotype was dependent upon the untimely activation of 
NEK7 by NEK9. To confirm this hypothesis, we made use of a constitutively active mutant 
version of NEK7. Previous studies had revealed that, in the absence of NEK9, NEK7 adopts 
an auto-inhibited conformation in which the side-chain of Tyrosine-97 blocks the active site 

































Strikingly, transient expression of the activated NEK7-Y97A mutant, but not wild-type NEK7, 
caused generation of similar elongated cytoplasmic protrusions in U2OS cells (Fig. 3B, C). 
Consistent with the lack of effect of NEK6 depletion, expression of the equivalent activated 
NEK6-Y108A mutant did not cause formation of cytoplasmic protrusions but rather caused 
cells to become more rounded. Real-time transwell assays indicated that the increase in cell 
migration induced by activated NEK9 was also dependent on NEK7 but not NEK6 and, as it 
was detected after 10 hours, unlikely to be explained by reduced proliferation (Fig. 3D, E; and 
Supp. Figs. S2C, D). 
 
To further address the role of NEK7 in this pathway, we established HeLa cell lines in which 
YFP tagged wild-type, catalytically-inactive (D179N) and constitutively-active (Y97A) versions 
of NEK7 were expressed under the control of a tetracycline inducible promoter (Supp. Fig. 
S3). Consistent with transient expression, inducible expression of activated NEK7 but not 
wild-type or kinase-inactive NEK7 resulted in the formation of microtubule rich cytoplasmic 
protrusions in interphase (Fig. 3F, G). Interestingly, protrusions that formed upon expression 
of activated NEK7 were lost upon depletion of NEK9 suggesting that NEK9 does not simply 
act upstream to enhance NEK7 catalytic activity (Fig. 3H). Together, these data indicate that 
the microtubule-dependent alteration of cell morphology and increased rate of migration that 
occur upon activation of NEK9 is dependent on NEK7, while similar changes induced upon 
activation of NEK7 require the presence of NEK9 protein. 
 
EML4 interacts with NEK9 and promotes cell migration 
To further explore the mechanism through which the NEK9-NEK7 pathway may cause this 
change in cell morphology and migration, myc-tagged wild-type NEK9 was 
immunoprecipitated from asynchronous cells and immune complexes analysed by mass 
spectrometry. Intriguingly, this identified not only tubulin, supporting the notion that NEK9 can 
interact with interphase microtubules, but also the microtubule-associated protein, EML4 
(Supp. Fig. S4A-C). Previous large-scale proteomic mapping had identified EML2, EML3 and 
EML4 as potential binding partners of NEK6 (Ewing et al., 2007), while we have recently 
found that EML4 can be phosphorylated by NEK6 and NEK7 in mitosis (Adib et al., 2019 
). Western blotting of immunoprecipitates prepared with antibodies against either NEK9 or 
EML4 confirmed interaction between endogenous EML4 and NEK9 in extracts prepared from 
asynchronous U2OS cells (Fig. 4A). Moreover, YFP-EML4 was found to co-precipitate as well 
as if not more strongly with the activated NEK9-RCC1 mutant than wild-type NEK9 (Fig. 4B). 
As described above, NEK9 binds directly through its C-terminal region (residues 810-828) to 
NEK7 and NEK6, an interaction that is normally blocked in interphase by competitive 
interaction with the LC-8 adaptor protein (Haq et al., 2015; Regue et al., 2011). Removal of 

































NEK9 kinase activity (Roig et al., 2002). This in turn enables autophosphorylation at Ser-944, 
which displaces LC-8 and allows interaction with NEK7 and NEK6 (Regue et al., 2011). 
Hence, we propose that activated NEK9 can potentially interact simultaneously with both 
EML4 and NEK7. 
 
To investigate whether the microtubule-dependent changes in cell morphology that result 
from expression of activated NEK9 and NEK7 may relate to its interaction with EML4, U2OS 
cell lines were generated that stably expressed YFP alone or YFP-EML4. Proteins of the 
predicted size were expressed as determined by Western blotting, while the YFP-EML4 
protein localized as expected to the microtubule network (Supp. Fig. S5A-C). In contrast to 
parental cells or cells expressing YFP alone, the YFP-EML4 cells exhibited a morphology 
similar to cells expressing activated NEK9 or NEK7 with extended cytoplasmic protrusions 
that were lost upon treatment with the microtubule depolymerizing agents, nocodazole or 
vinorelbine (Fig. 4C; and Supp. Fig. S5D). Individual cell tracking experiments as well as real-
time transwell migration assays revealed that expression of YFP-EML4 also led to an 
increased rate, distance and velocity of migration, but reduced straightness, compared to 
those expressing YFP alone (Fig. 4D; and Supp. Fig. S5 E-H). To test the relationship of 
EML4 and NEK9 in the generation of these phenotypes, proteins were depleted in the 
different stable cell lines. Depletion of EML4 did not prevent the alterations in cell morphology 
induced upon expression of activated NEK9 (Fig. 4E; and Supp. Fig. S5I). In contrast, 
depletion of NEK9 or NEK7 led to loss of cytoplasmic protrusions and reduced migration in 
cells expressing YFP-EML4 (Fig. 4G-I; and Supp. Fig. S5J, K). Furthermore, induced 
expression of catalytically-inactive NEK7 prevented formation of cytoplasmic protrusions in 
cells overexpressing EML4 (Fig. 4I). These data indicate that overexpression of EML4 
induces altered cell morphology and enhanced migration that is dependent upon NEK9 and 
NEK7, and can be blocked by expression of inactive NEK7. 
 
EML4 recruits NEK9 and NEK7 to microtubules 
To understand how NEK9 and NEK7 act downstream of EML4 to induce alterations in cell 
morphology and migration, we first examined which region of the EML4 protein may be 
responsible for interaction with NEK9. Co-immunoprecipitation experiments revealed that 
endogenous NEK9 could interact not only with full-length EML4 but also both the isolated 
NTD and TAPE domains (Fig. 4J). On the other hand, it did not interact with a shorter 
fragment of the NTD that only encompassed the trimerization motif. We then hypothesized 
that EML4 may promote recruitment of NEK9 to the microtubule cytoskeleton. To test this 
hypothesis, we examined the localization of endogenous NEK9 in cells expressing different 
EML4 constructs. In cells expressing the TAPE domain, endogenous NEK9 was mainly 
distributed in the cytoplasm with only faint detection on microtubules, whereas in cells 

































Fig. S6A). Meanwhile, using the stable HeLa:YFP-NEK7 cell line (as localization of 
endogenous NEK7 is difficult to detect with current antibodies), it was found that NEK7 was 
recruited to microtubules upon transfection of Flag-tagged EML4 NTD, but not the TAPE 
domain (Fig. 4M, N; and Supp. Fig. S6B). Together, these data suggest a model in which the 
EML4 NTD recruits both NEK9 and NEK7 to microtubules. This explains not only how EML4 
can act upstream of NEK9 and NEK7, but also why the NEK9 protein is required for activated 
NEK7 to promote microtubule-dependent changes in cell morphology and migration. 
 
 
EML4-ALK V3 and V5, but not V1 or V2, induce altered cell morphology and migration 
Considering their importance in cancer biology, we were intrigued to know whether EML4-
ALK fusion proteins might also alter cell morphology and migration. To explore this possibility, 
we generated U2OS cell lines with stable expression of the ALK kinase domain alone or four 
of the different EML4-ALK variants (Fig. 5A). These included the longer variants, V1 and V2, 
which encode unstable proteins that do not localise to microtubules, and the shorter variants, 
V3 and V5, which encode stable proteins that localise to microtubules (Richards et al., 2014; 
Richards et al., 2015). Strikingly, microscopic analysis revealed that those cells expressing 
the stable variants that localise to interphase microtubules (V3 and V5) formed extended 
cytoplasmic protrusions, whereas those cells expressing the unstable variants that do not 
localise to the microtubules (V1 and V2) did not (Fig. 5B-D). Furthermore, both individual cell 
tracking and real-time transwell assays revealed that expression of V3 and V5 stimulated cell 
migration with significant increases in distance and velocity, whereas expression of V1 and 
V2 did not (Fig. 5E-I). Hence, expression of the short EML4-ALK variants that localize to 
microtubules lead to altered morphology and enhanced migration as compared to cells 
expressing the longer EML4-ALK variants that do not localise to microtubules.  
 
Altered morphology and migration in EML4-ALK V3 cells depend on NEK9 and NEK7 
To determine whether the changes observed in cell morphology and migration induced by 
EML4-ALK V3 required catalytic activity of the ALK tyrosine kinase, we first generated U2OS 
stable cell lines with catalytically-inactive (D1270N) versions of EML4-ALK V1 and V3. This 
revealed that cells expressing the inactive mutant proteins had similar length cytoplasmic 
protrusions as those seen in cells expressing the wild-type proteins (Fig. 6A). Second, we 
determined the consequences on cell migration of treatment with the ALK inhibitor, crizotinib. 
This did not alter the rate of migration of U2OS cells expressing EML4-ALK V3 despite 
preventing ALK-dependent signalling in these cells as expected (Fig. 6B, C; and Supp. Fig. 
S7A). Hence, we conclude that the altered morphology and enhanced migration of cells 


































As all four EML4-ALK variants under analysis here contain the EML4-NTD that can interact 
with NEK9, we tested whether these oncogenic fusion variants also bind NEK9. Surprisingly, 
co-immunoprecipitation experiments showed that endogenous NEK9 interacts with EML4-
ALK V3 and V5, but not with V1 or the ALK domain alone (Fig. 6D). This reflects a similar 
difference in the ability of the variants to bind microtubules and, while the explanation remains 
unknown, it is possible that interaction with both NEK9 and microtubules is prevented in V1 
and V2 either by misfolding of the NTD in the presence of the partial TAPE domain or 
competing association with chaperones. Real-time transwell migration assays revealed that 
depletion of NEK9 and NEK7 significantly reduced the migration of cells expressing EML4-
ALK V3 or V5 (Fig. 6E, F; and Supp. Fig.S7B, C). Overexpression of wild-type EML4, as well 
as activated NEK9, can promote microtubule stabilization (Adib et al., 2019 
; Houtman et al., 2007). Hence, we wished to determine whether expression of EML4-ALK V3 
also caused a similar increase in microtubule stabilisation. Both Western blot analysis of 
acetylated tubulin expression and measurement of the rate of nocodazole-induced 
microtubule depolymerisation in live cells using the SiR-tubulin probe confirmed that cells 
expressing EML4-ALK V3 had increased microtubule stability as compared to cells expressed 
EML4-ALK V1 (Fig. 6G, H; and Supp. Fig. S7D). 
 
We then expressed EML4-ALK V1 and V3 in Beas-2B bronchial epithelial cells as an 
alternative model for lung disease (Supp. Fig. S8A). Parental Beas-2B cells exhibit a more 
elongated morphology than U2OS cells and their growth is subject to contact inhibition as 
expected for non-cancer derived cells. For this reason, these cells were not suitable for 
measuring changes in cell morphology or the rate of migration in a wound-healing assay. 
However, they do form three-dimensional (3D) spheroids when grown in ultra-low attachment 
plates allowing us to analyse the consequences of expression of these fusion variants on 3D 
migration into Matrigel. Strikingly, we found that expression of EML4-ALK V3, but not V1, led 
to the generation of extended chains of Beas-2B cells typical of collective cell migration (Fig. 
6I, J, K). Moreover, there was a significant reduction in the length of these chains if cells 
expressing EML4-ALK V3 were first depleted of NEK7 (Fig. 6L; and Supp. Fig. S8B). We 
therefore conclude that expression of EML4-ALK V3 but not V1 leads to NEK9 and NEK7-
dependent alterations in cell morphology and migration, as well as to stabilization of 
microtubules. 
 
EML4-ALK V3 NSCLC patient cells exhibit NEK9 and NEK7-dependent alteration of cell 
morphology and migration 
To determine whether the altered cell morphology and migration observed in U2OS cell lines 
might contribute to tumour progression in NSCLC patients, we first examined the morphology 

































variants. H3122 cells are derived from a NSCLC tumour that expresses V1, whereas H2228 
are derived from a NSCLC tumour that expresses V3. Brightfield microscopy revealed that 
whereas H3122 cells exhibit a cobblestone appearance, H2228 cells have a spindle-like 
morphology with extended cytoplasmic protrusions (Fig. 7A-C). As observed in U2OS cells, 
the protrusions present in H2228 cells were significantly reduced in length upon depletion of 
either NEK7 or NEK9 (Fig. 7D, E and Supp. Fig. S8C). Real-time transwell migration assays 
revealed that the H2228 cells exhibited a significantly increased rate of migration as 
compared to H3122 cells, while this was reduced by depletion of NEK7 or NEK9 (Fig. 7F-I). 
Individual cell tracking experiments indicated that depletion of NEK7 or NEK9 reduced the 
distance and increased the straightness of migration in H2228 but not H3122 cells (Fig 7J, K; 
and Supp. Fig. S8D, E). Again consistent with data in U2OS cells, the elongated protrusions 
present in H2228 cells were not affected by treatment with the ALK inhibitor crizotinib, 
whereas they were reduced upon depolymerisation of microtubules with nocodazole (Fig. 7L, 
M). Importantly, to confirm that the differences observed in H2228 cells compared to H3122 
cells were caused by the different EML4-ALK variant expressed, we first transfected H3122 
cells with YFP-EML4-ALK-V3. This caused a significant increase in the length of interphase 
cytoplasmic protrusions in H3122 cells (Fig 7N). Second, we depleted EML4-ALK V3 from 
H2228 cells and found that this led to a significant reduction in cytoplasmic protrusion length 
(Fig. 7O, P). Together, these data provide persuasive evidence that the different behaviour of 
these established NSCLC patient cells results from the different EML4-ALK fusion variant that 
they express. 
 
Lung cancer patients with EML-ALK V3 exhibit upregulation of NEK9 
Results in established cell lines suggest that the more aggressive properties associated with 
EML4-ALK V3 as compared to V1 may in part be caused by a NEK9-dependent pathway that 
promotes cell migration. This hypothesis would require NEK9 protein to be expressed in 
EML4-ALK V3 tumours. To test this, we used immunohistochemistry to examine NEK9 
expression in a cohort of primary tumours from patients with ALK-positive stage IV advanced 
lung adenocarcinoma. Remarkably, this revealed that while the majority of tumours 
expressing V1, V2 (or others) had low levels of NEK9 expression (64%, n=25), the majority of 
tumours expressing V3 or V5 had medium or high levels of NEK9 expression (91%, n=22) 
with an overall significant difference between the V1/V2/others and V3/V5 cohorts of p<0.001 
(Fig. 8A, B). Intriguingly, ALK-positive lung cancer patients with medium or high NEK9 
expression also exhibited worse progression-free (p=0.027) survival than patients with low 
NEK9 expression (Fig. 8C). Assessment of clinicopathological features revealed no 
association of NEK9 expression with gender, age or smoking history. However, EML4-ALK 
patients with low NEK9 expression had on average undergone more rounds of previous 
treatment suggestive of more prolonged and potentially less aggressive disease than those 

































required to define the molecular events that underpin the apparent link between elevated 
NEK9, EML4-ALK variant expression and survival. However, these findings raise the exciting 
possibility not only that these patients could be amenable to treatments that target NEK9 or 
NEK7, but also that this pathway represents an important mechanism through which variants 
that bind microtubules accelerate lung cancer progression (Fig. 8D). 
  
DISCUSSION 
A better understanding of the processes that drive progression and metastatic dissemination 
of EML4-ALK tumours is urgently required as this will identify opportunities for development of 
new therapeutic approaches to treat ALK inhibitor-resistant NSCLC. Here, we show that the 
short EML4-ALK variants, including the common V3, promote microtubule-dependent 
changes in cell morphology and enhance cell migration in both 2D and 3D models in a 
manner that could promote dysplastic development and metastasis. EML4-ALK V3 is 
associated with poor response to ALK inhibitors suggesting additional oncogenic mechanisms 
that are independent of ALK tyrosine kinase activity (Woo et al., 2017). Indeed, we found that 
the cellular changes induced by EML4-ALK V3 were not dependent on ALK activity. 
Experimentally, these short variants retain the capacity to bind microtubules, in contrast to the 
longer variants V1 and V2 that encode destabilizing fragments of the EML4 TAPE domain 
and rely on the HSP90 chaperone for expression (Richards et al., 2014). We speculate that 
either protein misfolding or chaperone interaction blocks the ability of the longer variants to 
associate with and regulate microtubules. We also show that the altered cell morphology and 
increased migration induced by the short EML4-ALK variants are dependent on the NEK9-
NEK7 kinase module. Hence, these data not only reveal a novel mechanism through which 
EML4-ALK variants could promote cancer progression, but also reveal new biomarkers and 
targets that could be exploited for the treatment of patients with these oncogenic fusions. 
 
NEK9 is required for assembly of the microtubule-based mitotic spindle. This is consistent 
with the kinase achieving maximal activity in mitosis following phosphorylation by the CDK1 
and PLK1 mitotic kinases (Fry et al., 2017). These phosphorylation events cause release of 
an auto-inhibited state that relies on the presence of an internal RCC1-like inhibitory domain 
(Roig et al., 2002). Upon inducible expression of an activated NEK9 mutant lacking this 
domain, we observed striking alterations in interphase cell morphology and enhanced cell 
migration. The mitotic functions of NEK9 are executed in part through phosphorylation of the 
microtubule nucleation adaptor protein, NEDD1/GCP-WD, and in part through activation of 
two other members of the NEK family, NEK6 and NEK7 (Belham et al., 2003; Kaneta and 
Ullrich, 2013; Roig et al., 2005; Roig et al., 2002; Sdelci et al., 2012). Interestingly, we found 
that depletion of NEK7, but not NEK6, prevented the altered cell morphology and enhanced 
migration observed in interphase cells arguing that activated NEK9 promotes these 

































expression of a constitutively active NEK7 but not NEK6 kinase. These findings are 
consistent with growing evidence that NEK7 has microtubule-associated functions in 
interphase cells, with depletion of endogenous NEK7 interfering with interphase microtubule 
dynamics, the centrosome duplication cycle and ciliogenesis (Cohen et al., 2013; Gupta et al., 
2017; Kim et al., 2011; Kim et al., 2007; Yissachar et al., 2006). Of particular interest to our 
findings, a kinase-dependent role was recently described for NEK7 in stimulating dendrite 
growth in post-mitotic neurons. This resulted from phosphorylation by NEK7 of the kinesin 
motor protein Eg5, which in turn led to stabilization of microtubules (Freixo et al., 2018). As 
EML4 is highly expressed in neurons, we speculate that modulation of microtubule 
organization leading to altered neuronal morphology and migration may represent the normal 
physiological role for the EML4-NEK9-NEK7 pathway identified here. However, NEK7 can 
phosphorylate other motor proteins to control microtubule organization and interact with 
additional regulators of the microtubule and actin networks, offering alternative mechanisms 
through which this pathway could operate (Cullati et al., 2017; de Souza et al., 2014). 
 
The discovery of EML4 as a binding partner for NEK9 provides new insight into how NEK9 
might regulate microtubule dynamics. The EMLs are a family of relatively poorly characterized 
MAPs (Fry et al., 2016). Humans have six EMLs of which EML1, 2, 3 and 4 share a similar 
organization consisting of an NTD that encompasses a trimerization motif and basic region 
that binds microtubules, and a C-terminal TAPE domain that binds tubulin heterodimers 
(Richards et al., 2014; Richards et al., 2015). The possibility that EMLs may be interacting 
partners of NEKs was first raised by a proteomic study that identified association of NEK6 not 
only with NEK7 and NEK9, but also EML2, EML3 and EML4 (Ewing et al., 2007). We 
identified EML4, as well as tubulin, in a mass spectrometry analysis for NEK9 binding 
partners, while interaction of endogenous EML4 and NEK9 was confirmed by Western 
blotting. Co-immunoprecipitation studies revealed that NEK9 can bind to the isolated NTD of 
EML4, as well as to the EML4-ALK V3 and V5 proteins. Interestingly, it did not bind to EML4-
ALK V1 despite this variant encoding the complete NTD. This suggests that misfolding or 
binding of chaperones might prevent interaction with NEK9 as well as microtubules. Further 
studies revealed that the EML4 NTD was capable of recruiting both NEK9 and NEK7 to 
microtubules. This suggests that binding of the EML4 NTD to microtubules and NEK9 are not 
mutually exclusive, although the fact that NEK9 and the EML4 NTD form dimers and trimers, 
respectively, means that this recruitment could rely on oligomerization of these proteins. We 
propose that recruitment of NEK7 relies on its direct interaction with NEK9, although do not 
rule out an independent interaction with EML4. However, the fact that NEK9 is required for 
these morphological consequences even in the presence of activated NEK7 suggest that 
NEK9 plays an essential role potentially in targeting NEK7 to its downstream substrates. 
Moreover, although we have shown that expression of activated NEK9 and EML4-ALK V3 
leads to stabilization of microtubules, further work is required to establish the mechanisms 


































Of major clinical significance is the fact that EML4-ALK fusion proteins act as oncogenic 
drivers in ~5% of NSCLC patients (Soda et al., 2007). Unscheduled activation of the ALK 
tyrosine kinase is primarily responsible for driving tumorigenesis as demonstrated by the fact 
that ALK inhibitors block transformation. First and second generation ALK inhibitors have 
revolutionized survival outcomes in ALK-positive lung cancer patients; however resistance is 
inevitable emerging through point mutations in the catalytic domain as well as through bypass 
pathways (Liao et al., 2015; Rolfo et al., 2014). Alternative targeted therapies would therefore 
be highly attractive and, in the case of the longer variants, HSP90 inhibitors could provide an 
option. The longer variants are unstable proteins as a result of expressing an incomplete 
fragment of the highly structured TAPE domain. In the absence of the HSP90 chaperone they 
are rapidly degraded by the proteasome leading to loss of downstream proliferative signalling 
(Richards et al., 2014). HSP90 inhibitors have been tested in ALK-positive patients although 
to date clinical trials have yet to prove their efficacy (Katayama et al., 2015; Workman and 
van Montfort, 2014). The short variants though are not dependent on HSP90 for their 
expression and HSP90 inhibitor treatment is unlikely to be effective. Moreover, EML4-ALK V3 
tumours appear less sensitive to ALK inhibitors in the first place emphasizing the need for 
alternative treatments for these particular patients (Woo et al., 2017). Demonstration that the 
downstream consequences on cell morphology and migration induced by these short variants 
is dependent on NEK9 and NEK7, but not ALK activity, raises the tantalizing prospect that 
inhibitors of this pathway may be beneficial in EML4-ALK V3 cancers where metastasis and 
ALK inhibitor resistance underpin lethality (Christopoulos et al., 2018). Although we have no 
evidence that inhibiting this pathway promotes cytotoxicity, the ability to block migration and 
invasion with so-called ‘migrastatics’ offers huge potential benefits in slowing disease 
progression in patients with solid cancers (Gandalovicova et al., 2017). 
 
The significant correlation in patient samples between elevated NEK9 expression and EML4-
ALK V3 is particularly intriguing as it implicates this pathway in the high metastatic potential of 
these tumours (Christopoulos et al., 2018; Doebele et al., 2012). However, although the 
association of elevated NEK9 with V3 and V5 was significant, expression does not 
necessarily reflect activation and it will be important in the future to assess the catalytic 
activity of NEK9 and NEK7 in these tumours. Moreover, we cannot rule out that tumour cells 
with this variant exert positive selection for high expression of NEK9 either due to its role as a 
downstream target or as a result of their increased aggressiveness. Nevertheless, the 
reduced progression-free survival of patients with increased NEK9 expression potentially 
explains the poor response of these patients to ALK-based therapies, despite the fact that the 
different EML4-ALK variants bind ALK inhibitors with similar affinity (Heuckmann et al., 2012). 

































ALK lung cancers and supports the hypothesis that targeting NEK9 or NEK7 could be 
beneficial in patients with EML4-ALK V3. 
 
Finally, it is interesting to note that EML proteins are involved in other oncogenic fusions, 
including the EML1-ABL1 fusion found in T-cell acute lymphoblastic leukaemia (ALL) (De 
Keersmaecker et al., 2005). Whether these also localise to microtubules and alter cell 
morphology and migration in a manner that is dependent on the microtubule network and the 
NEK9-NEK7 kinase module will be important to examine. Standard treatments for many 
cancers, including NSCLC and ALL, often involve microtubule poisons, such as vinorelbine or 
paclitaxel. Hence, it will also be worthwhile to explore the possibility that EML4-ALK variant 
status affects response to these drugs, and test whether there could be patient benefit in 
combining microtubule poisons with targeted agents against ALK, HSP90 or indeed NEK9 or 
NEK7. 
 
MATERIALS & METHODS 
Plasmid construction and mutagenesis 
Full-length EML4 cDNA was isolated by PCR from human cDNA (Clontech) and subcloned 
into a version of pcDNA3 or pcDNA3.1-hygro (Invitrogen) providing N-terminal YFP- or Flag-
tags. YFP-tagged EML4-ALK variants and fragments of EML4, and Flag-tagged NEK6 and 
NEK7 constructs were generated as previously described(O'Regan and Fry, 2009; Richards 
et al., 2014; Richards et al., 2015). A full-length Myc tagged cDNA expressing human NEK9 
(NM_001329237.1) was subcloned into the pVLX-Tight-Puro vector (Clontech). The RCC1 
domain was deleted using the Quickchange® II XL Site-Directed Mutagenesis Kit according 
to manufacturer’s instructions (Stratagene) using the primer sequences, 5’-
gctgtagtaacatcacgaaccagtatccgttccaatagcagtggcttatcc and 5’-
ggataagccactgctattggaacggatactggttcgtgatgttactacagc. Point mutations in the NEK7, NEK6 
and ALK catalytic domains were also introduced using the Quickchange® II XL Site-Directed 
Mutagenesis Kit. Constructs were confirmed by DNA sequencing (University of Leicester). 
 
Cell culture, drug treatments and transfection 
HeLa, U2OS and derived stable cell lines were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) with GlutaMAX™-I (Invitrogen) supplemented with 10% heat-inactivated fetal bovine 
serum (HI-FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin, at 37˚C in a 5% CO2 
atmosphere. H3122 and H2228 cells were grown in RPMI 1640 medium (Invitrogen) 
supplemented with 10% HI-FBS, 100 U/ml penicillin and 100 µg/ml streptomycin.  All cell lines 
were obtained from ATCC within the last 10 years, stored in liquid nitrogen and maintained in 

































for authenticity, while mycoplasma infection was avoided through bimonthly tests using an in-
house PCR-based assay. Doxycycline-inducible NEK9 stable U2OS cell lines were generated 
through lentiviral transduction of parental U2OS cells stably carrying the pVLX-Tet-On-
Advance vector (Clontech, PT3990-5). Briefly, NEK9 lentiviral particles for each construct 
were harvested from transfected 293T packaging cells using the Lenti-X™ HTX Packaging 
System (Clontech), transduced into U2OS parental cells and selected in fresh media 
supplemented with 2 mg/ml of G418 and 1 µg/ml puromycin over several days. To maintain 
expression of constructs, culture media was supplemented with 1 ug/ml of G418 and 800 
ng/ml of puromycin. For induction of constructs, doxycycline was added to growth media at a 
final concentration of 1 µg/ml for 72 h, unless otherwise stated. Doxycycline-inducible 
HeLa:YFP-NEK7 cell lines were generated via co-transfection of parental HeLa cells which 
stably express the lacZ-Zeocin™ fusion gene and Tet repressor from pFRT/lacZeo and 
pcDNA6/TR plasmids, respectively, with the appropriate pcDNA5/FRT/TO-YFP-NEK7 vector 
and the Flp recombinase expression vector, pOG44. After 48 h cells were incubated in 
selective media containing 200 µg/ml hygromycin B and resistant clones selected and 
expanded. To maintain expression in stable cell lines, media was supplemented with 200 
µm/ml hygromycin B (Invitrogen). For induction of NEK7 constructs, doxycycline was added 
at a final concentration of 1 µg/ml for 72 h unless otherwise stated. Constitutively expressing 
EML4 and EML4-ALK cell lines were generated by transfecting the relevant construct into 
U2OS cells. After 48 h cells were incubated in selective media containing 100 µg/ml 
hygromycin B (Invitrogen). To maintain expression in stable cell lines, media was 
supplemented with 100 µg/ml hygromycin. Where indicated, cells were treated with 200 ng/ml 
nocodazole (Sigma), 20 nM vinorelbine (Sigma) or 100 nM Crizotinib (Selleck). Transient 
transfections were performed with Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s instructions. For flow cytometry, cells were fixed in ice-cold 70% ethanol 
before DNA was labelled with 5 g/ml propidium iodide. Analysis was performed using a 
FACSCanto II instrument and FACSDiva software (BD Biosciences).  
 
Preparation of cell extracts, SDS-PAGE and Western blotting 
Cells were lysed in RIPA lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% v/v Nonidet P-
40, 0.1% w/v SDS, 0.5% w/v sodium deoxycholate, 5 mM NaF, 5 mM β-glycerophosphate, 30 
µg/ml RNase, 30 µg/ml DNase I, 1x Protease Inhibitor Cocktail, 1 mM PMSF) prior to analysis 
by SDS-PAGE and Western blotting. Primary antibodies were GFP (0.2 µg/ml, cat# ab6556, 
Abcam), α-tubulin (0.1 µg/ml, clone B512,cat# T5168, Sigma), myc (1:1000, clone 9B11 cat# 
2276, Cell Signalling Technologies), NEK9 (0.8 µg/ml, cat# sc-50765, Santa Cruz 
Biotechnology), EML4 (0.2 µg/ml, cat# A310-908A, Bethyl Laboratories), Flag (0.5 µm/ml, 
clone M2, cat# F3165, Sigma), acetylated tubulin (0.5 µg/ml, clone 6-11 B-1 cat# T6793, , 
Sigma) ALK (1:2000, cat# 3633, Cell Signaling technology), pALK (1:1000, cat# 3341, Cell 

































Secondary antibodies used were anti-rabbit, anti-mouse or anti-goat horseradish peroxidase 
(HRP)-labelled IgGs (1:1000; cat# A6154, A4416 and A5420, respectively,  Sigma). Western 
blots were detected using enhanced chemiluminescence (Pierce). 
 
RNAi 
Cells at 30–40% confluency were cultured in Opti-MEM Reduced Serum Medium and 
transfected with 50 nM siRNA duplexes using Oligofectamine (Invitrogen) according to the 
manufacturer’s instructions. 72 hours after transfection, cells were either fixed for 
immunocytochemistry or prepared for Western blot. siRNA oligos were directed against 
NEK9, AM51334-1113 and -1115 silencer select duplexes (Ambion) or EML4, HSS120688 
and Hss178451 On-Target Plus duplexes (Dharmacon); siRNA duplexes for NEK6 and NEK7 
were as previously described (O'Regan and Fry, 2009), 20. 
 
Immunoprecipitation, kinase assay and mass spectrometry 
Cells were harvested by incubation with 1x PBS+0.5 mM EDTA and pelleted by centrifugation 
prior to being lysed in NEB lysis buffer(Fry and Nigg, 1997). Lysates were 
immunoprecipitated using antibodies against NEK9 (0.8 µg/ml, cat# sc-50765, Santa Cruz 
Biotechnologies), EML4 (0.4 µg/ml, cat# A310-908A, Bethyl Laboratories), myc (1:1000, 
clone 9B11 cat# 2276, Cell Signaling Technologies) or GFP (0.2 µg/ml, cat# ab6556, Abcam). 
Proteins that co-precipitated with myc-NEK9 were excised from gels and subjected to in-gel 
tryptic digestion prior to LC-MS/MS using an RSLCnano HPLC system (Dionex, UK) and an 
LTQ-Orbitrap-Velos mass spectrometer (Thermo Scientific). The raw data file obtained from 
each LC-MS/MS acquisition was processed using Proteome Discoverer (version 1.4, Thermo 
Scientific), searching each file in turn using Mascot (version 2.2.04, Matrix Science Ltd.) 
against the human reference proteome downloaded from UniProtKB (Proteome ID: 
UP000005640). The peptide tolerance was set to 5 ppm and the MS/MS tolerance set to 0.6 
Da. The output from Proteome Discoverer was further processed using Scaffold Q+S (version 
4.0.5, Proteome Software). Upon import, the data was searched using X!Tandem (The Global 
Proteome Machine Organization). PeptideProphet and ProteinProphet (Institute for Systems 
Biology) probability thresholds of 95% were calculated from the decoy searches and Scaffold 
used to calculate an improved 95% peptide and protein probability threshold based on the 



































Fixed and time-lapse microscopy 
Cells grown on acid-etched coverslips were fixed and permeabilised by incubation in ice-cold 
methanol at -20˚C for a minimum of 20 min. Cells were blocked with PBS supplemented with 
3% BSA and 0.2% Triton X-100 prior to incubation with the appropriate primary antibody 
diluted in PBS supplemented with 3% BSA and 0.2% Triton X-100. Primary antibodies used 
were against GFP (0.5 µg/ml, cat# ab6556; Abcam); -tubulin (0.1 µg/ml, clone B512,cat# 
T5168, Sigma), myc (1:1000, clone 9B11 cat# 2276, Cell Signalling Technologies), Flag (0.5 
µg/ml, clone M2, cat# F3165, Sigma-Aldrich), NEK9 (0.8 µg/ml, cat# sc-50765, Santa Cruz 
Biotechnology), -tubulin (0.2 µg/ml, cat# T3559, Sigma). Secondary antibodies were Alexa 
Fluor 488, 594 and 647 donkey anti-rabbit, donkey anti-mouse and donkey anti-goat IgGs (1 
µg/ml; cat# A32790, A32744 and AS32849, respectively, Invitrogen). DNA was stained with 
0.8 µg/ml Hoechst 33258. For actin visualisation, cells were fixed using 3.7% formaldehyde 
and stained using phalloidin-TRITC (1:200). Imaging was performed on a Leica TCS SP5 
confocal microscope equipped with an inverted microscope (DMI6000 B; Leica) using a 63x 
oil objective (numerical aperture, 1.4). Z stacks comprising 30–50 0.3-µm sections were 
acquired using LAS-AF software (Leica), and deconvolution of 3D image stacks performed 
using Huygens software (Scientific Volume Imaging).  For super-resolution radial fluctuations 
(SRRF) microscopy a VisiTech infinity 3 confocal microscope fitted with Hamamatsu C11440 
-22CU Flash 4.0 V2 sCMOS camera and a Plan Apo 100 x objective (NA 1.47) was used. 
100 images from the same slice were captured per channel and processed using the nanoJ-
SRRF plugin in Fiji.  Immunohistochemistry with NEK9 antibodies (Abcam, ab138488; 1:500) 
was performed on NSCLC patients with EML4-ALK fusions.  
 
Phase contrast and time-lapse microscopy was carried out using a Nikon eclipse Ti inverted 
microscope using a Plan Fluor 10x DIC objective (NA 0.3) or a Plan Fluor 40x objective (NA 
1.3). Images were captured using an Andor iXonEM+ EMCCD DU 885 camera and NIS 
elements software (Nikon). For time-lapse imaging, cells were cultured in 6-well dishes and 
maintained on the stage at 37°C in an atmosphere supplemented with 5% CO2 using a 
microscope temperature control system (Life Imaging Services) with images acquired every 
15 min for ≥24 h. Videos were prepared using ImageJ (National Institutes of Health). Cell 
protrusions were measured using Fiji. The length of protrusion was defined as the distance 
from the edge of the nucleus of the cell to the furthest point of the plasma membrane. For 
each experiment 50 cells were measured per condition.    
 
Individual Cell Tracking Assays  
To allow automated detection of individual cells for tracking analysis cells were transfected 
with YFP alone and subjected to time lapse imaging as appropriate.  Individual cell tracking 

































spots function and subsequently the Imaris TrackLineage algorithm was used to identify 
movements or tracks of these cells through the entire time period and thus provide numerical 
values for parameters such as speed and distance. For each experiment 25 tracks were 
measured per condition. 
 
Live-cell microtubule stability assays 
For live cell microtubule stability assays cells were grown in µ-well 8 well chamber slides 
(ibidi). Cells were incubated with 25 nM SiR-Tubulin (Cytoskeleton Inc.) for 4 h prior to 
imaging, 10 images were captured prior to addition of nocodazole and the drug was then 
added and a further 15 images were captured. Z stacks comprising of approximately 10 0.5 
µm sections were captured every 30 s for 7 mins. Images were cropped to single cells and 
deconvolved prior to analysis in Matlab.  For each experiment 10 cells were measured per 
treatment.                  
 
Cell migration assays 
For scratch-wound assays, cells were grown to 95% confluency in 6 well dishes before a 
pipette tip was used to scrape a 0.5 - 1 µm line across the width of the well. Cells were 
washed 3-5 x in pre-warmed media and either imaged by time-lapse microscopy or incubated 
at 37oC for 6 h before being processed for immunofluorescence microscopy. Cell migration in 
real time was analysed using the xCELLigence Real-Time Cell Analyzer (RTCA) DC 
equipment (AECA Biosciences) and CIM-16 plates, a 16 well system where each well is 
composed of upper and lower chambers separated by an 8 μm microporous membrane. Cells 
were grown in serum free medium for 24 h before being seeded in serum free medium into 
the upper chamber; complete medium containing 10% FBS was used as a chemo-attractant 
in the lower chamber of the plate and migration determined as the relative impedance change 
(cell migration index) across microelectronic sensors integrated into the membrane, where 
cell migration index = (impedance at timepoint n/impedance in the absence of cells)/nominal 
impedance value. Measurements were taken every 15 mins for 48 h. 
 
3D Spheroid Invasion Assays 
Spheroids were grown in ultra-low attachment 96-well plates (Corning) for 24hr hours, before 
EML4-ALK expression was induced using 1ug/ml doxycycline and siRNA applied for a further 
72hr. On day 5, Matrigel (Corning) was added to wells at 2.5mg/ml and further induction and 
siRNA treatment applied. Spheroids were imaged at 0hr and 72hr after addition of Matrigel 
using a VisiTech infinity 3 confocal microscope fitted with Hamamatsu C11440 -22CU Flash 
4.0 V2 sCMOS camera and 10x/0.3 Pan Fluor DIC L/N objective. Resulting images were 
analysed using Fiji software.  10 invasive strands were measured per cell and 6 spheriods 



































All quantitative data represent means  SD of three independent experiments. Statistical 
analyses on data shown in histograms were performed using a one-tailed unpaired 
Student’s t test assuming unequal variance or a one-way analysis of variance followed by 
post hoc testing for analysis of 2 data sets and multiple data sets, respectively.   For RTCA 
cell migration data and microtubule stability assays, which generated line plots, the area 
under the curve was calculated for each data set and statistical analysis was performed on 
these data using either a one-tailed unpaired Students t-test assuming unequal variance (2 
data sets) or a one way ANOVA (more than 2 data sets). For patient data, statistical 
significance was calculated using 2 test. p-values represent *, p< 0.05; **, p< 0.01; ***, p< 
0.001. n.s., non-significant. 
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Figure 1. Constitutively active NEK9 induces altered morphology and stabilised 
microtubules in interphase cells 
A. Schematic representation of full-length and activated NEK9 indicating the kinase, RCC1 

































U2OS stable cell lines were induced to express wild-type (WT), catalytically-inactive (K81M) 
or constitutively-active (RCC1) myc-NEK9 for 0, 24, 48 and 72 h.  Lysates were prepared 
and analysed by Western blot with myc and -tubulin antibodies. U2OS cells with the 
tetracycline-inducible plasmid (empty vector, EV) were used as a negative control. C. Cells as 
in B were induced to express Nek9 proteins for 48 h prior to imaging by phase contrast 
microscopy; scale bar, 50 µm. D. The maximum length of cytoplasmic protrusions for cells in 
C is indicated. E. The percentage of cells with protrusions exceeding 40 µm for cells in C & D 
is indicated. F. Stills from time-lapse phase-contrast imaging of U2OS:myc-NEK9-RCC1 
cells +/- doxycycline for the times indicated; scale bar, 100 µm. G. Dox-Induced U2OS:myc-
NEK9-RCC1 were treated with DMSO, nocodazole or vinorelbine, analysed by phase-
contrast microscopy and maximum length of cytoplasmic protrusions measured.  H. 
U2OS:myc-NEK9-RCC1 cells were analysed by immunofluorescence microscopy with myc 
and acetylated tubulin antibodies and images reconstructed using SRRF analysis. I. 
U2OS:myc-NEK9-RCC1 cells were analysed by immunofluorescence microscopy with -
tubulin antibodies while actin was stained with phalloidin-FITC. Images were reconstructed 
using SRRF analysis. In H & I, magnified views of cytoplasmic protrusions are shown on the 
right from boxed regions in cells on the left. Scale bars, 20 µm (main image) and 5 µm 
(zooms). J. Cell lysates prepared from U2OS:myc-NEK9-WT and RCC1 cells were Western 
blotted with acetylated tubulin and GAPDH antibodies. The intensity of acetylated tubulin 
relative to GAPDH is indicated. K. U2OS:myc-NEK9-WT and RCC1 cells were incubated 






































Figure 2. Activated NEK9 disturbs cell polarity and increases cell migration 
A. U2OS:myc-NEK9-RCC1 or -EV (empty vector) were imaged to observe closure of a 
scratch wound. Representative images at time-points indicated are shown; scale bar, 200 µm. 
B. Rates of wound closure for cells in A is shown. C. The persistence of movement for cells at 
the leading edged of the wound generated as in A was measured by quantifying track 
straightness for each cell. D. U2OS:myc-NEK9-RCC1 or –EV were induced for 24 h, 
transfected with YFP for 24 h and subsequently imaged by time-lapse microscopy. Movement 

































distance travelled is colour-coded as indicated (µm). Scale bar, 100 µm. E. The mean 
distance travelled by cells treated as in D is indicated. F. The mean velocity of cells treated as 
in D is indicated. G. The persistence of movement for cells in D was measured by quantifying 
track straightness (track displacement/track length) for each cell. H. U2OS:myc-NEK9-WT, -
RCC1 or -EV were induced for 24 h before being starved in serum-free medium for a further 
24 h, and seeded in RTCA CIM-16 plates. Complete medium containing 10% FBS was used 
as a chemo-attractant and impedance measurements were used to determine cell migration 
in real time. I. The histogram shows the cell migration index at 10 h from the RTCA assays 




































     
Figure 3. NEK9-induced alterations in cell morphology and migration are dependent on 
NEK7  
A. U2OS:myc-NEK9-RCC1 cells were depleted as indicated. Cells were processed for 
immunofluorescence microscopy and maximum length of interphase cytoplasmic protrusions 
measured. B. U2OS cells were transiently transfected with wild type (WT) or constitutively 
active Flag-NEK6 (Y108A) or Flag-NEK7 (Y97A), as indicated, before being processed for 
immunofluorescence microscopy with Flag (green) and -tubulin (red) antibodies. DNA (blue) 

































cytoplasmic protrusions for cells in B. D. U2OS:myc-NEK9-RCC1 cells were depleted, as 
indicated and cell migration was analysed in real time as in 2H. E. Cell migration index at 10 h 
from the RTCA assays in D. F. HeLa:YFP, or YFP-NEK7-WT, D179N or Y97A cells were 
processed for immunofluorescence microscopy and the maximum length of interphase 
cytoplasmic protrusions measured. G. HeLa:YFP-NEK7-WT and Y97A cells were analysed 
by immunofluorescence microscopy with GFP (green) and -tubulin (red) antibodies. Scale 
bar, 20 µm. H. HeLa:YFP-NEK7-Y97A were depleted as indicated and cells were processed 
for immunofluorescence microscopy and maximum length of interphase cytoplasmic 




































    
 
Figure 4. EML4 induces NEK9-dependent changes in cell morphology and migration 
and recruits NEK9 and NEK7 to interphase microtubules 
A. U2OS cell lysates (inputs) and immunoprecipitates (IP) prepared with rabbit NEK9 and 
control IgGs were analysed by Western blot with antibodies indicated. B. U2OS:myc-NEK9-
WT or RCC1 cells were transfected with YFP-EML4 or YFP alone. Lysates (input) and 
Immunoprecipitates (IP) were prepared with GFP antibodies and analysed by Western blot 
with antibodies indicated. C. U2OS:YFP or U2OS:YFP-EML4 cell lines were treated as 
indicated for 16 h before analysis by phase contrast microscopy and maximum length of 

































EML4 cells was analysed in real time as in Fig. 2H. E. U2OS:myc-NEK9-RCC1 were 
depleted with mock or two different siRNAs against EML4 and the maximum length of 
interphase cytoplasmic protrusions measured. F. U2OS:YFP or U2OS:YFP-EML4 cells were 
depleted as indicated before being analysed by phase contrast microscopy and the maximum 
length of interphase cytoplasmic protrusions measured. G. U2OS:YFP-EML4 cells were 
depleted as indicated and cell migration was analysed in real time as in Fig. 2H. H. Cell 
migration index at 10 h from the data in G. I. HeLa:YFP-NEK7-WT or D179N were transfected 
with Flag-EML4 for 24 h and maximum length of cytoplasmic protrusions for transfected cells 
measured.  J. U2OS cells were transfected with YFP-EML4-full length (FL), TM (trimerisation 
motif), TAPE, NTD or YFP alone for 24 h. Lysates (inputs) and immunoprecipitates (IP) were 
prepared with GFP and control IgGs and analysed by Western blot with the antibodies 
indicated. Asterisks indicate the proteins of interest. K. U2OS cells were transfected with YFP 
alone or YFP-EML4 NTD before being processed for immunofluorescence microscopy with 
antibodies against GFP, NEK9 and -tubulin, and colocalization between the Nek9 and -
tubulin signal calculated. L. Representative images of cells in K. Scale bar, 10 µm. M. 
HeLa:YFP-NEK7 cells were transfected with flag alone or Flag-EML4-NTD for 24 h. Cells 
were processed for immunofluorescence microscopy with antibodies against Flag, GFP and 
-tubulin. Co-localization between the YFP-NEK7 fluorescence and -tubulin signal was 
calculated. N. Representative images of cells in M. R values in B and D show the mean 




































     
Figure 5. EML4-ALK variants that bind microtubules alter cell morphology and 
migration 
A. U2OS cell lines stably expressing YFP-tagged EML4-ALK fusion variants were lysed and 
analysed by Western blot with antibodies indicated. B. U2OS stable cell lines expressing 
YFP-tagged proteins as in A were analysed by immunofluorescence microscopy with 
antibodies against GFP (green) and -tubulin (red). DNA (blue) was stained with Hoechst 
33258. Magnified views of individual microtubules are shown on the right of V3 and V5 
images shown on the left. Schematic versions of the YFP-tagged proteins and the Pearson’s 
correlation coefficient (R) of co-localization with microtubules are shown. Scale bars, 10 µm. 
C. The maximum length of interphase cytoplasmic protrusions for cells in B. D. The % of cells 
from B and C with protrusions greater than 40 µm is indicated. E. Individual cell tracking 
experiments were undertaken with cell lines as in A and analysed as in Fig. 2D. The mean 
distance travelled is indicated. F. As for E, but showing mean velocity of movement. G. As for 
E but showing track straightness. H. Migration of cells as in A was analysed in real time as in 




































Figure 6. EML4-ALK V3 disturbs cell polarity, stabilises microtubules and binds NEK9 
A. U2OS cells were transfected with WT and Kinase Dead (KD) YFP-EML4-ALK-V1 and V3, 
as indicated, and analysed by immunofluorescence microscopy. The maximum length of 
interphase cytoplasmic protrusions for transfected cells was measured. B. U2OS:YFP-EML4-
ALK-V3 cells were treated with DMSO or 100 nM Crizotinib and cell migration analysed in 
real time as in Fig. 2H. C. Cell migration index at 10 h from data in B. D. U2OS:YFP-EML4-
ALK cells, as indicated, were lysed and lysates (inputs) and immunoprecipitates (IP) prepared 
with NEK9 antibodies or control IgGs analysed by Western blot with the antibodies indicated. 
E. U2OS:YFP-EML4-ALK-V3 cells were mock-, NEK6- or NEK7-depleted and cell migration 
analysed in real time as in Fig. 2H. F. Cell migration index at 10 h from data in E. G. Cell 
lysates prepared from U2OS:YFP-EML4-ALK-V1 and V3 cells were Western blotted with 
acetylated tubulin and GAPDH antibodies and the intensity of acetylated tubulin plotted 
relative to GAPDH. H. U2OS:YFP-EML4-ALK-V1 and V3 were incubated with SiR-Tubulin 
and SiR-Tubulin intensity measured following addition of nocodazole. Control cells were 
treated with DMSO. I.  Phase-contrast microscopy of invasion into Matrigel of dox-induced 
Beas-2B:EML4-ALK V1 and V3 at timepoints indicated. Scale bar, 100 µm J.  Length of 
invasive strand after 72 h for cells in I.  K.  Cells were treated as in I but fixed and actin 
stained with TRITC-phalloidin (red) and DNA with Hoechst 33258 (blue). Magnified views of 

































Scale bars, 20 µm (zooms), 100 µm (whole image)  L. EML4-ALK V3 cells were treated as in 
I except cells were also transfected with Nek7 siRNAs and length of invasive strand 



































   
Figure 7. Depletion of NEK7 or NEK9 reduces migration of NSCLC patient cells 
expressing microtubule-binding EML4-ALK variants 
A. H3122 and H2228 cells were analysed by phase contrast microscopy. B. Maximum length 
of interphase cytoplasmic protrusions for each cell type. C. The % of cells from A and B with 
protrusions greater than 40 µm is indicated. D. H2228 cells were depleted with NEK7 or 
NEK9 siRNAs and the maximum length of cytoplasmic protrusions measured. E Phase 
contrast images of cells treated in D. F. H3122 and H2228 cell migration was analysed in real 
time as in Fig. 2H. G. Cell index at 10 h for cells in F is shown. H. H2228 cells were depleted 
as indicated and migration analysed in real time as in Fig. 2D. I. Cell migration index at 10 h 
for cells in H is shown. J & K. H2228 cells that were mock- or NEK9-depleted were analysed 
by individual cell tracking as in Fig. 2D. Mean distance travelled (J) and track straightness (K) 

































maximum length of interphase cytoplasmic protrusions measured, control cells were treated 
with DMSO. N. H3122 cells were transfected with either YFP alone or YFP-EML4-ALK V3 
and the maximum length of interphase cytoplasmic protrusions for transfected cells 
measured. O. Lysates were prepared from H2228 cells that were mock transfected or 
transfected with two alternative siRNAs (siEML4 #3 & 4) designed to target the portion of 
EML4 found in the EML4-ALK-V3 expressed in H2228 cells and Western blotted as indicated. 
P. Maximum length of interphase cytoplasmic protrusions for cells treated as in O. Scale bars 






































































Figure 8. Elevated NEK9 expression correlates with EML4-ALK V3/V5 genotype in 
NSCLC patient tumours as well as poor overall survival 
A. Tumour biopsies from NSCLC patients were processed for immunohistochemistry with 
NEK9 antibodies (brown) and scored as low (1+), medium (2+) or high (3+). Tissue was also 
stained with haematoxylin to detect nuclei (blue). B. Table indicates NEK9 expression as 
determined as in A with respect to the EML4-ALK variant present. C. The Kaplan-Meier plot 
indicates progression-free survival of NSCLC patients with EML4-ALK fusion that had low 
(1+) or medium/high (2+/3+) NEK9 expression (n=32). D. Schematic model showing rationale 
for stratification of cancer patients for treatment based on EML4-ALK variant. (i) The majority 
of tumours expressing EML4-ALK V1/V2 express low levels of NEK9. In these cells, the 
EML4-ALK protein neither binds NEK9 nor colocalises with microtubules, and cells retain a 
more rounded morphology. (ii) However, the majority of tumours expressing EML4-ALK 
V3/V5 express moderate or high levels of NEK9. In these cells, the EML4-ALK protein binds 
and recruits NEK9 and NEK7 to microtubules leading to localised kinase activity that 
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Figure S1. Characterisation of doxycycline-inducible U2OS:myc-NEK9 constructs 
A. U2OS:myc-NEK9-WT, DRCC1 or K81M cells, or cells containing empty vector, were either 
uninduced (- dox) or induced (+ dox) for 72 h before being processed for immunofluorescence 
microscopy with myc (red) antibodies. B. U2OS:myc-NEK9-WT, DRCC1 or K81M cells were 
induced for 72 h before being fixed, stained with propidium iodide and analysed by flow 
cytometry. The percentage of cells in G1, S and G2/M are indicated. C. Cells were treated as 
in A and analysed by immunofluorescence microscopy with myc (green) and a-tubulin (red) 
antibodies. In A & C, DNA was stained with Hoechst 33258 (blue); scale bars, 20 µm. D. 
U2OS:myc-NEK9-DRCC1 cells were treated for 48 hours +/- doxycycline before incubation with 
SiR-Tubulin to visualise microtubules. SiR-Tubulin intensity was then measured every 15 s 
following addition of nocodazole. Stills from movies are shown. Scale bar, 10 µm. 



















































































































































Figure S2. Depletion of NEK6 and NEK7 in NEK9-DRCC1 cell lines 
A. U2OS:myc-NEK9-DRCC1 cells were mock-depleted or depleted with NEK6 or NEK7 siRNAs 
for 24 h prior to induction with doxycycline for a further 48 h. Cell lysates were prepared and 
analysed by Western blot with myc, NEK6, NEK7 and a-tubulin antibodies. B. U2OS:myc-
NEK9-DRCC1 cells were mock-depleted, or depleted with siNEK6.1 or siNEK7.1 and 
processed for immunofluorescence microscopy with myc (red) and a-tubulin (green) 
antibodies. DNA was stained with Hoechst 33258. Scale bar, 20 µm. C. U2OS:myc-NEK9-
DRCC1 cells were treated as in A and analysed using the live cell transwell migration assay. 
Data represent means from 3 separate experiments. D. Histogram shows the cell migration 
index at 10 h based on data in C. 
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Figure S3. Characterisation of doxycycline-inducible HeLa:YFP-NEK7 constructs 
Lysates prepared from HeLa stable cell lines induced to express wild-type (WT), catalytically-
inactive (D179N) or constitutively-active (Y97A) YFP-NEK7 with doxycycline for 0, 24 and 48 h 
were analysed by Western blot with GFP and a-tubulin antibodies. M. wts (kDa) are indicated 
on the left. 










































# Identified Proteins (3) Accession NumberMolecular Weight UL00825GB - 02 - Con UL00825GB - 01 - Nek9
1 Serine/threonine-protein kinase Nek9 OS=Homo sapiens GN=NEK9 PE=1 SV=2 Q8TD19 107 kDa ! 29




Figure S4. Identification of EML4 as a NEK9 binding partner by mass spectrometry 
A. Anti-myc immunoprecipitates prepared from U2OS:myc-NEK9-WT cells induced with 
doxycycline for 48 hours were analysed by SDS-PAGE and mass spectrometry. Eight peptides 
representing EML4 were identified in the immunoprecipitates from myc-NEK9 expressing cells, 
whereas no EML4 peptides were identified in immunoprecipitates from parental U2OS cells. B. 
The table shows peptides identified from human EML4 by LC-MS/MS. C. MS/MS spectrum of 
peptide WFVLDAETR; y-ion fragments highlighted in blue, b-ion fragments in red. Inset shows 
full fragmentation table. 








































































































































































































































































































































































Figure S5. Characterization of U2OS:YFP and U2OS:YFP-EML4 stable cell lines 
A. Lysates prepared from U2OS:YFP and U2OS:YFP-EML4 cell lines were Western blotted 
with the antibodies indicated. B. Immunofluorescence microscopy images of U2OS:YFP and 
U2OS:YFP-EML4 cell lines stained with GFP (green) and a-tubulin (red) antibodies. DNA (blue) 
is stained with Hoechst 33258. Scale bar, 20 µm. C. Representative intensity profiles along a 
single line-scan showing co-localization of YFP or YFP-EML4 with microtubules. R values show 
the mean Pearson's correlation coefficient from 10 cells. D. Phase contrast microscopy of 
U2OS:YFP and U2OS:YFP-EML4 cell lines. Scale bar, 100 µm. E. Individual cell tracking 
experiments were undertaken with U2OS:YFP and U2OS:YFP-EML4 cell lines and analysed 
as in Fig. 2D. The mean distance travelled is indicated. F. The mean velocity of cells treated 
as in E is indicated. G. The track straightness of cells treated as in E is indicated. H. The 
histogram shows the cell migration index at 10 h from the data in Fig 4D. I. Lysates prepared 
from U2OS:myc-NEK9-DRCC1 cells depleted for EML4 with two siRNAs or mock-depleted for 
24 h prior to induction with doxycycline for a further 48 h were analysed by Western blot for 
endogenous EML4 and actin. J. Lysates prepared from U2OS:YFP and U2OS:YFP-EML4 
cells, which had been depleted for NEK7 or NEK9 or mock depleted for 72 h, were Western 
blotted for NEK7, NEK9, GFP or a-tubulin.  K. U2OS:YFP or U2OS:YFP-EML4 cell lines were 
depleted of NEK7 or NEK9, as indicated, before analysis by phase contrast microscopy; scale 
bar, 100 µm. M. wts (kDa) are indicated on the left in A, E and F. 


















































































Figure S6. EML4-NTD recruits NEK9 and NEK7 to microtubules 
A. U2OS cells were transfected with YFP-EML4 N-terminal domain (NTD) or TAPE domain 
(TAPE), as indicated, for 24 h before being processed for immunofluorescence microscopy with 
antibodies against GFP (green) and NEK9 (red). B. HeLa:YFP-NEK7 cells were induced for 48 
h with doxycycline before being mock transfected or transfected with Flag-EML4-NTD or TAPE 
for a further 24 h. Cells were then processed for immunofluorescence microscopy with 
antibodies against Flag (green) and GFP (red). Merge images include DNA stained with 
Hoechst 33258 (blue). Scale bars, 10 µm. 
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Figure S7. Inhibition of ERK phosphorylation by crizotinib and stabilization of 
microtubules in EML4-ALK V3 cells 
A. Cell lysates prepared from U2OS:YFP-EML4-ALK-V3 cells treated with DMSO or Crizotinib 
at the concentrations indicated for 8 h were analysed by Western blot with ERK, pERK and a-
tubulin antibodies. B. . U2OS:YFP-EML4-ALK-V3 cells were mock-, NEK6- or NEK7-depleted 
for 72 h and cell migration analysed in real time as in Fig. 2M. C. The histogram shows the cell 
migration index at 10 h from data in B. D. U2OS:YFP-EML4-ALK V1 or V3 cells were incubated 
with SiR-Tubulin to visualise microtubules before SiR-Tubulin intensity was measured every 15 
s following addition of DMSO or nocodazole. Stills from movies are shown. Scale bars, 10 µm. 


















































































































































































Figure S8. Validation of siRNA depletion of NEK7 and NEK9 in EML4-ALK Beas-2B and 
NSCLC cells  
A.  Beas-2B:EML4-ALK v1 or v3 U2OS were treated with doxycycline for 48 h to induce protein 
expression.  Cell lysates were prepared and analysed by Western blot with the antibodies 
indicated. B. Beas-2B:EML4-ALK v3 cells were induced for 24 h prior to depletion for NEK7. 
Cell lysates were analysed by Western blot with the antibodies indicated.  C. H3122 or H2228 
cell lysates depleted for NEK6, NEK7 or NEK9 as indicated were analysed by Western blot with 
NEK7, NEK9 and a-tubulin antibodies. D. & E. H3122 cells that were mock, NEK7 or NEK9-
depleted for 48 h were analysed by individual cell tracking. The mean distance travelled (D) 
and track straightness (E) is shown.  M. wts (kDa) in A, B & C are indicated on the left. 



































 Parameters N (%) 
 Sex 
    Male 27 (49.1) 
    Female 28 (50.9) 
 Age in years, median (range) 54 (27 - 79) 
 Smoking history 
    Never 37 (67.3) 
    ≤10 pack-years 8 (14.5) 
    >10 pack-years 10 (18.2) 
 Number of previous chemotherapy 
    0 38 (69.1) 
    1 11 (20.0) 
    ≥ 2 6 (10.9) 
 Follow up in months, median (range) 15 (1 - 54) 
Table S1. Clinicopathological characteristics of EML4-ALK NSCLC patients 
182 ALK-positive patients with advanced NSCLC at Asan Medical Center (Seoul, Korea) were 
collected between June 2011 and August 2015. Of those, 113 patients were treated with the 
ALK inhibitor and had an Eastern Cooperative Oncology Group (ECOG) performance status 
between 0 and 3. Among 93 enrolled patients who were tissue-available and approved by the 
institutional review board, 38 were excluded because of poor quality of insufficient tissue 
samples and follow-up loss. For the analysis of the remaining 55 patients, medical records were 
reviewed to extract clinicopathological data including sex, age, smoking status, therapeutic 
agents, and survival. Of those, ALK subtyping was performed in 32 samples due to 23 cases 
with low quality of nucleic acid. All statistical analyses were carried out in the R software 
(version 3.3.3, the R Foundation for Statistical Computing, Vienna, Austria). 



































 Parameters - N (%) Score 1+ (N=22) Score 2+/3+ (N=33) P value* 
 Sex 1.000 
    Male 11 (50) 16 (48.5) 
    Female 11 (50) 17 (51.5) 
 Age in years, median (range) 55 (27 - 75) 54 (37 – 76) 0.911 
 Smoking history 0.390 
    Never 14 (63.6) 23 (69.7) 
≤10 pack-years 5 (22.7) 3 (9.1) 
    >10 pack-years 3 (13.6) 7 (21.2) 
 Number of previous therapy 0.071 
    0 13 (59.1) 25 (75.8) 
    1 4 (18.2) 7 (21.2) 
≥ 2 5 (22.7) 1 (3.0) 
 Follow up in months, median (range) 15 (2 - 50) 15 (1 - 54) 0.486 
. 
Table S2. Clinicopathological characteristics of EML4-ALK NSCLC patients 
according to NEK9 expression 
Based on the patients described in Supplementary Table S1, no clinicopathological 
characteristics exhibited a significant difference in relation to NEK9 expression. However, the 
number treated with previous chemotherapy was close to the borderline for significance 
(p=0.071) in that the proportion of patients treated with first line ALK inhibitor therapy was larger 
in the high Nek9 expression (score 2+/3+) group than the low expression (score 1+) group. 
This means that the low expression group included more intensively treated patients suggestive 
of more advanced NSCLC. This factor may affect the survival difference in the two groups 
treated with the ALK inhibitor. 
J. Cell Sci.: doi:10.1242/jcs.241505: Supplementary information
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